CAJ | 학술논문

目的:评价拉米夫定对乙型肝炎肝硬化患者的临床疗效.方法:将107例乙型肝炎肝硬化患者随机分为对照组(55例)和治疗组(52例).对照组给予常规保肝治疗,治疗组在常规治疗基础上加用拉米夫定(100mg/d),疗程1年.比较、观察两组患者肝功能、Child-Pugh评分、HBV DNA阴转率、肝纤维化指标(HA、LN、PⅢP、Ⅳ-C)的变化.结果:对照组、治疗组总有效率分别为61.8%、86.5%,两者之间有统计学差异(P<0.01).治疗组患者治疗1年后肝功能、肝纤维化指标、Child-Pugh评分及HBV DNA阴转率均较对照组显著改善(P<0.05).结论:拉米夫定可抑制HBV DNA的复制,有效提高丙氨酸氨基转移酶的复常率,改善肝功能.
목적:평개랍미부정대을형간염간경화환자적림상료효.방법:장107례을형간염간경화환자수궤분위대조조(55례)화치료조(52례).대조조급여상규보간치료,치료조재상규치료기출상가용랍미부정(100mg/d),료정1년.비교、관찰량조환자간공능、Child-Pugh평분、HBV DNA음전솔、간섬유화지표(HA、LN、PⅢP、Ⅳ-C)적변화.결과:대조조、치료조총유효솔분별위61.8%、86.5%,량자지간유통계학차이(P<0.01).치료조환자치료1년후간공능、간섬유화지표、Child-Pugh평분급HBV DNA음전솔균교대조조현저개선(P<0.05).결론:랍미부정가억제HBV DNA적복제,유효제고병안산안기전이매적복상솔,개선간공능.
Objective:To analysize the clinical effect of lamivudine on hepatitis B cirrhosis patients.Methods:107 patients with hepatitis B cirrhosis were randomly divided into control group (55 patients) and treatment group (52 patients). The control group received traditional liver-protecting therapy alone, while the treatment group received additional lamivudine (100 mg/d, 1 year). The liver function, Child-Pugh grade, HBV DNA and liver fibrosis markers (HA, LN, PⅢP andⅣ-C) were observed.Results:The total effective rate in treatment group (86.5%) was higher than that in control group (61.8%) (P<0.01). There were significant differences of liver fibrosis markers (HA, LN, PⅢP andⅣ-C), liver function, Child-Pugh grade and HBV DNAbetween treatment group and control group after treatment (P<0.05).Conclusion:Lamivudine controls the copy of HBV DNA, improves liver function effectively and finally achieves the treatment goal against liver cirrhosis.